Close Menu

    Subscribe to Updates

    Get the latest creative news from FooBar about art, design and business.

    What's Hot

    Chevron Signs 3-Year Agreement with UptimeAI, Scaling Expertise to Enhance Asset Reliability and Operational Efficiency

    November 17, 2026

    Tunisia tourism revenues top $2.38 billion by end-October

    November 17, 2026

    ALIF Holding Plans to Establish ALIF Terra for Arid-Land Agriculture and Land Rehabilitation

    November 17, 2026
    Facebook X (Twitter) Instagram
    • Home
    • Contact Us
    Port Said DailyPort Said Daily
    • Automotive
    • Business
    • Entertainment
    • Health
    • Lifestyle
    • Luxury
    • News
    • Sports
    • Technology
    • Travel
    Port Said DailyPort Said Daily
    Home » Wegovy sales weaken in US pushing Novo Nordisk to cut yearly guidance
    Featured News

    Wegovy sales weaken in US pushing Novo Nordisk to cut yearly guidance

    July 30, 2025
    Facebook Twitter LinkedIn Telegram Pinterest Tumblr Reddit Email
    Share
    Facebook Twitter LinkedIn Pinterest Email

    Shares of Danish pharmaceutical company Novo Nordisk fell sharply by 20% on Tuesday after the company cut its full-year sales and profit outlook and named a new chief executive officer. The market reaction came amid ongoing challenges in the U.S. market for the company’s widely used obesity and diabetes drugs.

    Novo Nordisk now expects full-year 2025 sales growth of 8% to 14%, down from its previous projection of 13% to 21%. Operating profit growth is expected to range between 10% and 16%, also lower than the prior estimate of 16% to 24%. The company cited slower-than-anticipated sales of its weight-loss drug Wegovy and diabetes treatment Ozempic in the second half of the year as key drivers of the revised outlook.

    The company also announced that Maziar Mike Doustdar will take over as president and CEO, effective August 7. A Novo Nordisk veteran since 1992, Doustdar most recently served as executive vice president for international operations. His appointment follows the unexpected departure of Lars Fruergaard Jørgensen, whose removal was announced in May after a prolonged decline in the company’s stock performance.

    Wegovy and Ozempic sales pressure second-half performance

    Despite reporting a 40% increase in second-quarter operating profit and an 18% rise in sales year-on-year, Novo Nordisk warned of slower momentum for the remainder of the year. It noted that compounded GLP-1 drugs continue to impact demand for Wegovy in the U.S., even after the expiration of a temporary exemption granted by the U.S. Food and Drug Administration (FDA) earlier in 2025.

    Competition in the weight-loss drug market has also intensified. Prescriptions for rival Eli Lilly’s weight-loss drug Zepbound surpassed those of Wegovy in March. In addition, Novo Nordisk has faced negative sentiment following disappointing clinical trial results for its next-generation obesity candidate, CagriSema.

    Stock price falls over 50 percent year-to-date

    The company is actively pursuing legal and regulatory strategies to combat the impact of unauthorized compounded drugs in the U.S. market. Executives have indicated that they expect availability of copycat drugs to decline in the second half of the year, but uncertainty remains regarding the pace of recovery in U.S. sales. Novo Nordisk’s stock has declined more than 50% over the past year.

    Tuesday’s selloff erased significant gains made during the prior year’s Ozempic-driven rally, which had briefly made Novo Nordisk the most valuable listed company in Europe. Analysts say investors will be watching closely for the company’s full second-quarter earnings report, scheduled for release on August 6, as well as updates on its product pipeline and regulatory developments. – By Eurowire News Desk.

    Share. Facebook Twitter Pinterest LinkedIn Tumblr Email

    Related Posts

    Network International and AdalFi Partner to Unlock Data-Driven Lending Across the Middle East and Africa

    November 16, 2026

    TCL Donates Ultra-Low-Power Display System to the Youth Olympic Village, Bringing Advanced Display Technology to Everyday Use

    November 12, 2026

    MENA Newswire Launches AfricaWire Distribution Network

    October 19, 2026

    Dataroid Recognized in the Gartner® Market Guide for Product Analytics (2026)

    October 6, 2026

    Wibmo Fraud & Risk Management wins Chartis Disruptor Award for its Agentic Risk Intelligence Solution

    September 28, 2026

    VitrA Tiles Introduces “The Code” concept and the New Codes of Design at Cersaie Fair

    September 25, 2026
    Latest News
    Travel

    Tunisia tourism revenues top $2.38 billion by end-October

    November 17, 2026

    – Tunisia’s tourism revenues exceeded $2 billion by the end of October, rising 3.4% from the same period last year. Receipts reached 7.152 billion Tunisian dinars, or about $2.384 billion, Minister of Tourism Sofiane Tekaya told parliament on Sunday. More

    UAE President and Venezuela’s acting leader discuss closer ties

    November 17, 2026

    Etihad to fly daily between Abu Dhabi and Calgary from 2027

    November 17, 2026

    Africa CDC says Congo Ebola outbreak still not under control

    November 16, 2026

    UAE and Timor-Leste presidents discuss stronger bilateral ties

    November 16, 2026

    UAE President, Arab League chief discuss regional security

    November 14, 2026

    AfDB backs Morocco reforms and climate resilience with €434.4m

    November 14, 2026
    © 2026 Port Said Daily | All Rights Reserved
    • Home
    • Contact Us

    Type above and press Enter to search. Press Esc to cancel.